Cisplatin, 5-fluorouracil, and cetuximab (PFE) with or without cilengitide in recurrent/metastatic squamous cell carcinoma of the head and neck: results of the randomized phase I/II ADVANTAGE trial (phase II part)

Vermorken, JB; Peyrade, F; Krauss, J; Mesía, R; Remenar, E; Gauler, TC; Keilholz, U; Delord, JP; Schafhausen, P; Erfán, J; Brümmendorf, TH; Iglesias, L; Bethe, U; Hicking, C; Clement, Paul

doi:10.1093/annonc/mdu003

Cisplatin, 5-fluorouracil, and cetuximab (PFE) with or without cilengitide in recurrent/metastatic squamous cell carcinoma of the head and neck: results of the randomized phase I/II ADVANTAGE trial (phase II part)

Author:

Vermorken, JB

Peyrade, F ; Krauss, J ; Mesía, R ; Remenar, E ; Gauler, TC ; Keilholz, U ; Delord, JP ; Schafhausen, P ; Erfán, J ; Brümmendorf, TH ; Iglesias, L ; Bethe, U ; Hicking, C ; Clement, Paul

Keywords:

Science & Technology, Life Sciences & Biomedicine, Oncology, cetuximab, cilengitide, integrin inhibitor, phase I/II, platinum-based chemotherapy with 5-fluorouracil, recurrent and/or metastatic squamous cell carcinoma of the head and neck (R/M-SCCHN), CHEMOTHERAPY PLUS CETUXIMAB, RECURRENT, CANCER, INTEGRINS, SAFETY, Adult, Aged, Antibodies, Monoclonal, Humanized, Antimetabolites, Antineoplastic, Antineoplastic Agents, Antineoplastic Combined Chemotherapy Protocols, Biomarkers, Tumor, Carcinoma, Squamous Cell, Cetuximab, Cisplatin, Disease Progression, Disease-Free Survival, ErbB Receptors, Female, Fluorouracil, Head and Neck Neoplasms, Humans, Male, Middle Aged, Snake Venoms, Squamous Cell Carcinoma of Head and Neck, Treatment Outcome, 1112 Oncology and Carcinogenesis, Oncology & Carcinogenesis, 3202 Clinical sciences, 3211 Oncology and carcinogenesis

Abstract:

Recurrent and/or metastatic squamous cell carcinoma of the head and neck (R/M-SCCHN) overexpresses αvβ5 integrin. Cilengitide selectively inhibits αvβ3 and αvβ5 integrins and is investigated as a treatment strategy.